Abstract
The introduction of novel antimyeloma therapies, including thalidomide, lenalidomide, and bortezomib, has expanded treatment options for patients with this disease. These compounds have altered the natural history of multiple myeloma, resulting in substantial improvements in patient outcomes. However, like with any other drug, their use is associated with a specific toxicity profile. The major adverse events (AEs) associated with lenalidomide include: hematological toxicities (myelosuppression), mainly neutropenia, venous thromboembolism, gastrointestinal disturbance, skin toxicity, atrial fibrillation, asthenia, and decreased peripheral blood stem cell yield during stem cell collection when lenalidomide is used after a long period of time. These AEs are predictable, consistent, and manageable with patient monitoring, supportive care, and dose adjustment. In this article, using three clinical cases as examples, we discuss the diagnoses and management of the most frequent AEs associated with lenalidomide treatment in patients with multiple myeloma.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111:2516–2520.
Sirohi B, Powles R. Epidemiology and outcomes research for MGUS, myeloma and amyloidosis. Eur J Cancer. 2006;42:1671–1683.
Clinical Trials.gov: a service of the US National Institutes of Health. Search of studies with lenalidomide and newly diagnosed multiple myeloma. Available at: http://clinicaltrials.gov/ct2/results?term=lenalidomide+and+newly+diagnosed+multiple+myeloma. Accessed December 14, 2010.
Engelhardt M, Kleber M, Udi J, et al. Consensus statement from European experts on the diagnosis, management, and treatment of multiple myeloma: from standard therapy to novel approaches. Leuk Lymphoma. 2010;51:1424–1443.
Ludwig H, Beksac M, Bladé J, et al. Current multiple myeloma treatment strategies with novel agents: a European perspective. Oncologist. 2010;15:6–25.
Weber DM, Chen C, Niesvizky R, et al. Multiple Myeloma (009) Study Investigators. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med. 2007;357:2133–2142.
Dimopoulos M, Spencer A, Attal M, et al. Multiple Myeloma (010) Study Investigators. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med. 2007;357:2123–2132.
Chen C, Reece DE, Siegel D, et al. Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma. Br J Haematol. 2009;146:164–170.
Stadtmauer EA, Weber DM, Niesvizky R, et al. Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma. Eur J Haematol. 2009;82:426–432.
Ishak J, Dimopoulus MA, Weber D, Knight RD, Shearer A, Caro J. Declining rates of adverse events and dose modifications with lenalidomide in combination with dexamethasone. Blood (ASH Annual Meeting Abstracts). 2008;112:3708.
Rajkumar SV, Jacobus S, Callander NS, Fonseca R, Vesole DH, Williams ME. Eastern Cooperative Oncology Group. Lenalidomide plus highdose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an openlabel randomised controlled trial. Lancet Oncol. 2010;11:29–37.
Baz R, Walker E, Karam MA, et al. Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy. Ann Oncol. 2006;17:1766–1771.
Knop S, Gerecke C, Liebisch P, et al. Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom). Blood. 2009;113:4137–4143.
Palumbo A, Falco P, Corradini P, et al. GIMEMA-Italian Multiple Myeloma Network. Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA-Italian Multiple Myeloma Network. J Clin Oncol. 2007;25:4459–4465.
Niesvizky R, Jayabalan DS, Christos PJ, et al. BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma. Blood. 2008;111:1101–1109.
Chanan-Khan AA, Yu Z, Weber D, et al. Lenalidomide (L) in combination with dexamethasone (D) significantly improves time to progression (TTP) in non-stem cell transplant patients (pts) with relapsed or refractory (rel/ref) multiple myeloma (MM): analysis from MM-009 and MM-010 randomized phase III clinical trials. Blood (ASH Annual Meeting Abstracts). 2006;108:3554.
Reece D, Masih-Khan, Chen C, et al. Lenalidomide (Revlimid) costicosteroid in elderly patients with relapsed/refractory multiple myeloma. Blood (ASH Annual Meeting Abstracts). 2006;108:3550.
Palumbo A, Rajkumar SV, Dimopoulus MA, et al. International Myeloma Working Group. Prevention of thalidomide and lenalidomide associated trombosis in myeloma. Leukemia. 2008;22:414–423.
Weber D, Rankin K, Gavion M, Dalasalle K, Alexanian R. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol. 2003;21:16–19.
Neben K, Moehler T, Benner A, et al. Dosedependent effect of thalidomide on overall survival in relapsed multiple myeloma. Clin Cancer Res. 2002;8:3377–3382.
Zangari M, Anaissie E, Barlogi B, et al. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood. 2001;98:1614–1615.
Zonder JA, Barlogie B, Durie DG, Mc Coy J, Crowley J, Hussein MA Thrombotic complications in patients with newly diagnosed multiple treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis. Blood (ASH Annual Meeting Abstracts). 2006;108:403.
Brandenburg NA, Goss TF, Knight T, Xu X, Knight RD. Evaluation of the relationship between venous thromboembolism risk factors and the use of antithrombotic prophylaxis in multiple myeloma patients treated with thalidomide and dexamethasone combination regimens. Blood (ASH Annual Meeting Abstracts). 2008;112:2369.
Zangari M, Tricot G, Poavaram L, et al. Survival effect of venous thromboembolism in patients with multiple myeloma treated with lenalidomide and high dose dexamethasone. J Clin Oncol. 2009;28:132–135.
Wright JA, Weber D, Thomas SK, et al. Characteristics of patients experiencing thomboembolic events during treatment for multiple myeloma: aspirin may not be adequate thromboprophylaxis in patients with multiple risk factors. Blood (ASH Annual Meeting Abstracts). 2007;110:1882.
Klein U, Kosely F, Hillegab J, et al. Effective prophylaxis with low molecular weight heparin in relapsed multiple myeloma patients treated with lenalidomide and dexamethasone. Ann Hematol. 2009:88:67–71.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Persona, E.P., Mesa, M.G., Sánchez, P.J.G. et al. Lenalidomide treatment for patients with multiple myeloma: Diagnosis and management of most frequent adverse events. Adv Therapy 28 (Suppl 1), 11–16 (2011). https://doi.org/10.1007/s12325-010-0102-x
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12325-010-0102-x